At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 70 enrolled
Drug / intervention
Colistimethate Sodiumdrug
Likely dose
Colistimethate Sodium 2.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections
In Brief
A Phase 4 clinical trial evaluating Colistimethate Sodium for Gram-Negative Bacterial Infections and 4 related conditions. Completed, enrolled 70 participants across 1 site.
Detailed Summary
Prospective randomized study comparing different colistin dosing regimens in paediatric cancer patient with MDR gram-negative infection or sepsis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGram-Negative Bacterial Infections, Pediatric Cancer, Colistin, Colistin Adverse Reaction, MIC
CountriesEgypt
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedJan 2018
Primary CompletionJan 2019
Study CompletionMar 2019
TodayJul 2026
First PostedJan 12, 2018
Enrollment StartJan 1, 2017
Primary CompletionJan 1, 2019
Study CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 8.5 years ago
Interventions
Colistimethate Sodiumdrug
Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections